Neumora Therapeutics, Inc. NMRA
0.50 USD +0.02 (+3.35%)
At closeNov 6, 2026, 6:12 PM EST
0.52 +0.02 +3.32%
After hours · Nov 6, 6:12 PM ET
0.4703 Day range 0.5699
0.315 52-week range 3.65
- YTD
- -71.88%
- 1 year
- -80.49%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose…
benzinga.com Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of…
benzinga.com Why Is BioAge Labs Stock Sinking Friday? BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
benzinga.com Neumora Therapeutics Reported Favorable Preclinical Toxicology Results From NMRA-215, An Oral NLRP3 Inhibitor In Development For Obesity And Cardiometabolic Disease; Plans To Submit An IND Application In Q4 Of 2026 Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of…
benzinga.com RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5 RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.
benzinga.com Datadog, EHang Holdings And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures rise, Nasdaq 100 up 1%. Datadog (DDOG) downgraded, pre-market trading. Other decliners: CNCK, SLBT, MBGL, ZIM, GRVY, TALO, DPC, NMRA, FIP, HKD, EH, PSNY.- benzinga.com Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4 Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $6 to $4.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey.…- benzinga.com Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5 Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $8 to $5.
benzinga.com HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7 HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $18 to $7.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
benzinga.com Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial…
benzinga.com Dow Jumps Over 600 Points Following US-Iran Peace Deal US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.- benzinga.com Neumora Therapeutics Says Navacaprant Did Not Achieve Primary Endpoint In KOASTAL-2 Or -3; Company To Discontinue Development Of Navacaprant Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of…
benzinga.com 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive Health officials explored restricting specific antidepressants among SSRI drugs-sources- benzinga.com Neumora Therapeutics Q1 EPS $(0.30) Beats $(0.33) Estimate Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 28.57 percent increase over losses of…
benzinga.com Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.- benzinga.com Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $14 price target.
benzinga.com Needham Reiterates Buy on Neumora Therapeutics, Maintains $8 Price Target Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $8 price target.- benzinga.com Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 7.36 percent. This is a 5.41 percent increase over losses…
benzinga.com Earnings Scheduled For March 30, 2026 
benzinga.com Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts 
benzinga.com Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.
benzinga.com William Blair Upgrades Neumora Therapeutics to Outperform William Blair analyst Myles Minter upgrades Neumora Therapeutics (NASDAQ:NMRA) from Market Perform to Outperform.- benzinga.com Leerink Partners Initiates Coverage On Neumora Therapeutics with Outperform Rating, Announces Price Target of $8 Leerink Partners analyst Marc Goodman initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Outperform rating and announces Price Target of $8.
- benzinga.com Neumora Therapeutics Says KOASTAL-2 And -3 On Track For Consolidated Topline Readout In Q2 2026; Plans To Conduct NMRA-215 Clinical Program In 2026 Following Preclinical Data From Diet Induced Obesity Model Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationKOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026Plans to…
- benzinga.com Neumora Therapeutics Announces Results From Phase 1b Signal-Seeking Study Of NMRA-511 In People With Alzheimer's Disease Agitation NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a…
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Neumora's Alzheimer's Agitation Drug Shows Early Promise NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety profile.
benzinga.com Neumora Therapeutics Lays Out 2026 Drug Pipeline Milestones, Highlights Obesity and Depression Programs Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of…- benzinga.com Neumora Therapeutics Reports Results From NMRA-511 Phase 1b Signal-Seeking Study In People With Alzheimer's Disease Agitation NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket 
benzinga.com Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.
benzinga.com This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - benzinga.com RBC Capital Upgrades Neumora Therapeutics to Outperform, Raises Price Target to $7 RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perform to Outperform and raises the price target from $4 to $7.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com This Warner Bros. Discovery Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session